{"id":"W2050379741","doi":"10.1158/0008-5472.sabcs13-p3-13-03","title":"Abstract P3-13-03: A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): Effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Capecitabine; Internal medicine; Eribulin; Hazard ratio; Anthracycline; Proportional hazards model; Oncology; Progression-free survival; Taxane; Breast cancer; Metastatic breast cancer; Cancer; Confidence interval; Surgery; Chemotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002867683,0.002149873,0.00339657,0.0004765459,0.0005439389,0.00135117,0.001343612,0.001986096,0.009331778],"category_scores_gemma":[0.002015514,0.0007366615,0.001775608,0.0007142206,0.001693744,0.00116056,0.0004715529,0.005218903,0.001481619],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009917109,"about_ca_system_score_gemma":0.00278595,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001359732,"about_ca_topic_score_gemma":0.003487245,"domain_scores_codex":[0.9990765,0.0005661313,0.00004660123,0.0001269254,0.00006001439,0.0001238323],"domain_scores_gemma":[0.9986299,0.0003713358,0.0002339371,0.00009653589,0.00008705004,0.0005812656],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9708055,0.01321427,0.0004835153,0.0003490093,0.0005251103,0.00004090091,0.00004096556,0.0002684265,0.00354559,0.0001018768,0.0008247569,0.009800084],"study_design_scores_gemma":[0.9151597,0.08278998,0.0008225795,0.00001475262,0.0001934907,0.00002183626,0.00001326359,0.000264982,0.0003026241,0.00008966742,0.0003192611,0.000007892385],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9789949,0.002513075,0.001194802,0.00110063,0.0004459611,0.01082084,0.00248421,0.0002010371,0.002244563],"genre_scores_gemma":[0.9741865,0.001973641,0.003005127,0.002010201,0.0005255869,0.01190871,0.001794911,0.00005663259,0.004538614],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009331778,"threshold_uncertainty_score":0.03121793,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07583385628773552,"score_gpt":0.4838298686528856,"score_spread":0.40799601236515,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}